Cumulative probability of prostate cancer detection in biopsy according to free/total PSA ratio in men with total PSA levels of 2.1-10.0 ng/ml at population screening

Journal of Cancer Research and Clinical Oncology

Volumn 140, Issue 1, 2014, Pages 53-59

  Kitagawa, Yasuhide ^a   Ueno, Satoru ^a   Izumi, Kouji ^a   Kadono, Yoshifumi ^a   Konaka, Hiroyuki ^a   Mizokami, Atsushi ^a   Namiki, Mikio ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

Free total PSA ratio; Prostate cancer; PSA; Risk factor; Screening

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGE; AGED; ARTICLE; CANCER PATIENT; CANCER SCREENING; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; JAPANESE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROBABILITY; PROSTATE BIOPSY; PROSTATE CANCER; TRANSRECTAL ULTRASONOGRAPHY;

EID: 84892668672     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-013-1543-9     Document Type: Article

References (21)

1. Andriole GL, Levin DL, Crawford ED, et al. (2005) Prostate cancer screening in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial: findings from the initial screening round of a randomized trial. J Natl Cancer Inst 97:433-438 (Pubitemid 40528606)
2. Argangeli CG, Humphrey PA, Smith DS, et al. (1998) Percentage of free serum prostate-specific antigen as a predictor of pathologic features of prostate cancer in a screening population. Urology 51:558-565 (Pubitemid 28186207)
3. Aus G, Becker C, Franzén S, Linja H, Lodding P, Hugosson J (2004) Cumulative prostate cancer risk assessment with the aid of the free-to-total prostate specific antigen ratio. Eur Urol 45:160-165 (Pubitemid 38147821)
4. Bouchardy C, Fioretta G, Rapiti E, et al. (2008) Recent trends in prostate cancer mortality show a continuous decrease in several countries. Int J Cancer 123:421-429 (Pubitemid 351842029)
5. Cancer International Union Against (1997) Urologic tumors: prostate. In: Sobin LH, Wittekind CH (eds) TNM classification of malignant tumours, 5th edn. John Wiley and Sons, New York, pp 170-173
6. Carter HB, Albertsen PC, Barry MJ, et al. (2013) Early detection of prostate cancer: AUA guideline. J Urol 190:419-426
7. Catalona WJ, Smith DS, Ratliff TL, et al. (1991) Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. New Engl J Med 324:1156-1161
8. Crawford ED, Moul JW, Rove KO, et al. (2011) Prostate-specific antigen 1.5-4.0 ng/ml: a diagnostic challenge and danger zone. BJU Int 108:1743-1749
9. Finne P, Auvinen A, Määttänen L, et al. (2008) Diagnostic value of free prostate-specific antigen among men with a prostate-specific antigen level of <3.0 μg/l. Eur Urol 54:362-370 (Pubitemid 351885247)
10. Ishidoya S, Ito A, Orikasa K, et al. (2008) The outcome of prostate cancer screening in a normal Japanese population with PSA of 2-4 ng/ml and the free/total PSA under 12%. Jap J Clin Oncol 38:844-848
11. Ito K, Yamamoto T, Ohi M, et al. (2003) Free/total PSA ratio is a powerful predictor of future prostate cancer morbidity in men with initial PSA levels of 4.1-10.0 ng/ml. Urology 61:760-764 (Pubitemid 36384969)
12. Kakehi Y, Kamoto T, Shiraishi T, et al. (2008) Prospective evaluation of selection criteria for active surveillance in Japanese patients with stage T1cN0M0 prostate cancer. Jpn J Clin Oncol 38:122-128 (Pubitemid 351337956)
13. Kitagawa Y, Mizokami A, Nakashima K, et al. (2011) Clinical outcomes of prostate cancer patients detected by prostate-specific antigen-based population screening in Kanazawa city. Jpn Int J Urol 18:592-596
14. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A (2010) Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 28:126-131
15. Kobori Y, Kitagawa Y, Mizokami A, Komatsu K, Namiki M (2008) Free-to-total prostate-specific antigen (PSA) ratio contributes to an increased rate of prostate cancer detection in a Japanese population screened using a PSA level of 2.1-10.0 ng/ml as a criterion. Int J Clin Oncol 13:229-232 (Pubitemid 351871889)
16. Orsted DD, Nordestgaard BG, Jensen GB, Schnohr P, Bojesen SE (2012) Prostate-specific antigen and long-term prediction of prostate cancer incidence and mortality in the general population. Eur Urol 61:865-874
17. Pannek J, Rittenhouse HG, Chan DW, et al. (1998) The use of percent free prostate specific antigen for staging clinically localized prostate cancer. J Urol 159:1238-1242 (Pubitemid 28172805)
18. Pelzer AE, Volgger H, Bektic J, et al. (2005) The effect of percentage free prostate-specific antigen (PSA) level on the prostate cancer detection rate in a screening population with low PSA levels. BJU Int 96:995-998 (Pubitemid 41531401)
19. Roddam AW, Duffy MJ, Hamdy FC, et al. (2005) Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2-10 ng/ml: systematic review and meta-analysis. Eur Urol 48:386-399 (Pubitemid 41188392)
20. Schröder FH (2001) Diagnosis, characterization and potential clinical relevance of prostate cancer detected at low PSA ranges. Eur Urol 39:49-53 (Pubitemid 32429660)
21. Thompson IM, Pauler DK, Goodman PJ, et al. (2004) Prevalence of prostate cancer among men with a prostate-specific antigen levels ≤4.0 ng/ml. N Engl J Med 350:2239-2246 (Pubitemid 38669206)